Atypical defects resulting in growth hormone insensitivity

Area of Science:

• Endocrinology
• Genetics
• Immunology

Background:

• Growth hormone insensitivity (GHI) has well-documented genetic causes (GHR, STAT5B, IGF1, IGFALS defects).
• Other congenital and acquired conditions are also associated with GHI, affecting downstream signaling pathways.
• Growth hormone (GH) signaling involves a complex cascade including GHR, JAK2, STAT5b, MAPK, and PI3K pathways.

Purpose of the Study:

• To explore non-genetic factors and novel genetic syndromes associated with GHI.
• To investigate the role of the NF-κB pathway in GHI and immune dysfunction.
• To elucidate the molecular mechanisms underlying GHI in a patient with a 17q21-25 duplication.

Main Methods:

• Literature review of GHI causes.
• Case study analysis of patients with GHI and immune deficiencies.
• Molecular studies on patient-derived cells (lymphocytes, fibroblasts) to assess signaling pathways (NF-κB, STAT5, PI3K, MAPK).

Main Results:

• Acquired conditions like estrogen deficiency, corticosteroid excess, sepsis, and renal failure can affect GHI.
• Noonan syndrome and rasopathies inhibit JAK/STAT via RAS-MAPK pathway; Sotos syndrome shows downregulation.
• A patient with IκBα mutation exhibited reduced NF-κB, STAT5, and PI3K activity.
• A 17q21-25 duplication syndrome patient showed suppressed NF-κB, PI3K, and STAT5, but increased MAPK sensitivity to GH, linked to PRKCA overexpression.

Conclusions:

• The NF-κB pathway is implicated in GH signaling and immune function.
• Novel genetic syndromes, such as 17q21-25 duplication, can cause GHI with associated immune defects.
• Understanding these complex interactions is crucial for diagnosing and managing GHI.